What do Aimovig, Ajovy, and Emgality have in common? Migraine for one, but more importantly, they are a class of monoclonal antibodies (mAbs) targeting calcitonin gene-related peptides (CGRPs). Some pretty smart people figured out that by blocking CGRPs in our bodies, just maybe they can also block attacks in people with chronic migraine. For me, personally, I started Aimovig back in June 2018. It’s been a great experience for me and I look forward to fewer migraine days ahead. It’s exciting and I’m so grateful to be able to utilize this medication. But it hasn’t been perfect and I still have attacks.
